Company intelligence / Profile preview

IntegriMedical

Ownership: Private
Development stage: Commercial

Overview

Clinical trials have shown that N-FIS significantly reduces pain during drug administration and addresses needle-phobia. The system has received regulatory approvals including CE mark, MDSAP certification, CDSCO approval in India, ISO 13485 certification, and holds a US patent. It is being introduced to the Indian private market with plans for global expansion through partnerships like Serum Institute of India.

Therapeutic areas: Other
Modalities: DeviceDrug delivery technology
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

NFIS

Commercial

Indications: Drug delivery, Vaccine administration

Partnerships

Serum Institute of India (SII): Strategic partnership/investment to expand access to needle-free injection systems globally.

Beyond the preview

Go deeper on IntegriMedical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IntegriMedical.

Explore the full profile